The Johns Hopkins University

Michael Goggins

Bert Vogelstein

Kenneth W Kinzler

Nickolas Papadopoulos

Norihiro Sato

Victor E Velculescu

Ralph Hruban

Sian Jones

D Williams Parsons

Scott E Kern

Giovanni Parmigiani

Rachel Karchin

Manuel Medina Hidalgo

James R Eshleman

Sato Norihiro

Takashi Ueki

Alison Klein

Tatsuo Hata

Philipp Angenendt

Donald William Parsons

Jimmy Chang-Ho Lin

Described are telomere fusion assays to detect dysplasia in subjects using nested primers. The methods of the present invention are able to detect dysplasia in subjects with intraductal papillary mucinous neoplasma (IPMNs), for example.

Telomere fusions and their detection of dysplasia and/or cancer

The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

Diagnostic method using PALB2

The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject.

Aberrantly methylated genes in pancreatic cancer

The present invention includes methods diagnosising of cancer by analysis of a patient sample, particularly for the presence of a methylated SPARC nucleic acid molecule, and particularly for the diagnosis of pancreatic cancer. The invention also includes therapeutic methods for treating cancers by administering to cancers patients therapeutically effective amounts of demethylating agents.

Methylated gene biomarkers for detecting cancer

The present invention provides a method for detecting a cellular proliferative disorder in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.

Differentially methylated sequences in pancreatic cancer

Growing community of inventors

Baltimore, MD, United States of America

Michael Goggins